Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Biogen

Biogen's Q3 2024 Earnings: What to Expect

Biogen will release its third-quarter earnings this month, and analysts anticipate a double-digit profit dip.

What Does A Double Bottom Base Look Like? This Top Biotech Stock Formed A Great One

What Does A Double Bottom Base Look Like? This Top Biotech Stock Formed A Great One

Bioverativ formed a perfect double bottom, a key chart pattern for growth stock hunters, and broke out ahead of its big 61% gain on news it's being bought by Sanofi.

Investors Business Daily

Is Biogen Stock Underperforming the Dow?

Is Biogen Stock Underperforming the Dow?

Biogen has underperformed the Dow over the past year, but analysts are moderately optimistic about the stock’s prospects.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Revolution Or Mirage? Controversy Surrounds New Alzheimer's Drugs

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years.

International Business Times

Is Wall Street Bullish or Bearish on Biogen Stock?

Despite Biogen’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately bullish about the stock’s prospects.

Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review

The stock market took a bearish turn amid economic fears. Apple and Meta had strong results, while AI spending remains robust.

Investors Business Daily

Biogen Stock Slips As Alzheimer's Drug Looks Abroad For Quarterly Beat

Biogen stock slipped early Thursday despite a second-quarter beat that included strong of its new Alzheimer's treatment, Leqembi.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug

Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug

Biogen stock tumbled Friday after European regulators rejected its Eisai-partnered Alzheimer's treatment, citing steep side effects.

Investors Business Daily

Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails

Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails

Sage Therapeutics said Wednesday its Biogen-partnered treatment for essential tremor failed in a study, leading Sage stock to collapse.

Investors Business Daily

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong

Ionis Pharmaceuticals stock surged Monday after the company unveiled promising results for a drug that treats a rare genetic condition.

Investors Business Daily

Biogen Earnings Preview: What to Expect

Biogen Earnings Preview: What to Expect

Biogen is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.

Three Surprising Names That Could Be On Biogen's Buyout Shortlist

Three Surprising Names That Could Be On Biogen's Buyout Shortlist

Biogen stock has mostly trended sideways this year, but that could soon change with up to $10 billion in dry powder, an analyst said Tuesday.

Investors Business Daily

Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug

Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug

Eli Lilly won FDA approval for its Alzheimer's treatment, donanemab, on Tuesday. But Eli Lilly stock remained in the red.

Investors Business Daily

Is Biogen Stock Underperforming the Nasdaq?

Is Biogen Stock Underperforming the Nasdaq?

Biogen underperforms the Nasdaq Composite, and analysts remain cautiously optimistic about the stock’s prospects.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower

Eli Lilly stock seesawed Tuesday after a Food and Drug Administration panel endorsed its Alzheimer's treatment, donanemab.

Investors Business Daily

FDA Panelists Unanimously Back Eli Lilly's Biogen-Rivaling Alzheimer's Drug

Eli Lilly stock jumped Monday after FDA advisors said the benefits of Alzheimer's treatment donanemab outweigh the risks for most patients.

Investors Business Daily

How To Invest: Using Shorter-Term Moving Averages To Trade Stocks

Whether to use the 10-day, 21-day, 50-day and other moving averages, the question is, which one is best?

Biogen And Ionis Halt ALS Treatment Development

Biogen and Ionis discontinue ALS treatment development, emphasizing the need for continued research in neurodegenerative diseases.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Biogen Stock Continues Its 24% Sprint On A Twist In Alzheimer's Treatment

Biogen stock jumped Wednesday after the FDA gave its Eisai-partnered Alzheimer's treatment a fast track designation.

Investors Business Daily

Biogen Stock Surges After Two Notable Products Walloped Sales Expectations

Two of Biogen's newest drugs walloped first-quarter sales expectations on Wednesday, and helped Biogen stock jump.

The Guardian - UK

People with MND in England and Wales fear losing access to life-extending drug

NHS cost threshold has not been raised by National Institute for Health and Care Excellence since 2004

Investors Business Daily

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.

Stocks Give Up Early Gains and Close Lower as Chip Stocks Retreat

The S&P 500 Index ($SPX ) (SPY ) Friday closed down -0.65%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.18% and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.53%. Stock indexes on Friday gave up early gains and closed moderately lower. Stocks on...

International Business Times

Highly Awaited Alzheimer's Drug Hit By Delays

Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.

Investors Business Daily

Biogen Surges On A Setback For Eli Lilly's Rival Alzheimer's Treatment

Biogen stock jumped Friday after the FDA delayed its approval decision on Eli Lilly's rival Alzheimer's treatment, donanemab.

People

Christopher Raymond

Robert Kelly Ortberg

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Intel Corporation

British Petroleum

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Alzheimer Disease

Places

294,121 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play